Drug · FAERS side-effect profile with label screen
Hypromellose side effects: what 2,370 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Splash Refresh
openFDA label
Who reports
2,370 reports · 74% serious · 163 with death outcome · 72% female
openFDA FAERS counts, all years, deduplication not applied
Used for
Temporarily relieves burning and irritation due to dryness of the eye. discomfort due to minor irritations of the eye or to exposure to wind or sun.
FDA label, Indications and Usage
Boxed warning
None in the current label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation.
Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)?
That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.
Causality screen of the 37 strongest signals
Reporting / coding artifact 3Lab value / disease marker 2No label text to screen 32
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 37 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
Show:
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Eye irritation | 162 | 25.8 22.2–29.9ROR 27.6 · χ² 3,833 / p <1e-300 | 25.6 EB05 22.5 · IC025 +4.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 14.7 · 71% consumer | no trial data cached |
| Eye pain | 137 | 22.0 18.7–25.9ROR 23.3 · χ² 2,726 / p <1e-300 | 21.9 EB05 19.0 · IC025 +4.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 11.5 | no trial data cached |
| Eye discharge | 24 | 20.8 14.0–31.0ROR 21.0 · χ² 433 / p 2e-96 | 20.5 EB05 14.4 · IC025 +3.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=6 | no trial data cached |
| Photophobia (light sensitivity) | 32 | 15.2 10.8–21.4ROR 15.4 · χ² 410 / p 2e-91 | 14.9 EB05 10.9 · IC025 +3.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.0 | no trial data cached |
| Lacrimation increased | 49 | 14.5 11.0–19.2ROR 14.8 · χ² 604 / p 1e-133 | 14.3 EB05 11.2 · IC025 +3.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 9.5 | no trial data cached |
| Ocular hyperaemia | 73 | 13.8 11.0–17.4ROR 14.3 · χ² 858 / p 8e-189 | 13.7 EB05 11.2 · IC025 +3.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.5 | no trial data cached |
| Eye pruritus | 48 | 12.9 9.7–17.1ROR 13.1 · χ² 515 / p 3e-114 | 12.6 EB05 9.8 · IC025 +3.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 10.8 | no trial data cached |
| Urosepsis | 13 | 12.5 7.3–21.5ROR 12.6 · χ² 126 / p 2e-29 | 11.0 EB05 6.2 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 9.7 | no trial data cached |
| Ocular discomfort | 14 | 11.4 6.8–19.3ROR 11.5 · χ² 123 / p 8e-29 | 10.0 EB05 5.8 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=2 | no trial data cached |
| Supraventricular tachycardia | 11 | 10.2 5.6–18.4ROR 10.2 · χ² 82 / p 6e-20 | 8.3 EB05 4.5 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 8.3 | no trial data cached |
| Dry eye | 54 | 9.9 7.6–12.9ROR 10.1 · χ² 422 / p 4e-94 | 9.5 EB05 7.5 · IC025 +2.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 8.9 | no trial data cached |
| Eyelid oedema | 13 | 9.8 5.7–16.9ROR 9.9 · χ² 94 / p 1e-22 | 8.2 EB05 4.8 · IC025 +2.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 1.7 | no trial data cached |
| Hyponatraemia (low sodium) | 58 | 9.1 7.1–11.8ROR 9.3 · χ² 413 / p 4e-92 | 8.8 EB05 7.0 · IC025 +2.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.3 · ♀ 45% (drug 72%) · 90% clinician | no trial data cached |
| Liver function test abnormal | 30 | 9.1 6.4–13.0ROR 9.2 · χ² 208 / p 2e-47 | 8.4 EB05 6.0 · IC025 +2.4 3/3 methods agree | Reporting / coding artifact | serious PRR 8.8 | no trial data cached |
| Inappropriate antidiuretic hormone secretion | 10 | 8.7 4.7–16.2ROR 8.7 · χ² 61 / p 3e-15 | 6.8 EB05 3.8 · IC025 +1.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.8 | no trial data cached |
| Vision blurred (blurred vision) | 126 | 8.2 6.9–9.7ROR 8.6 · χ² 790 / p 4e-174 | 8.0 EB05 6.9 · IC025 +2.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.8 | no trial data cached |
| Lip swelling | 30 | 8.0 5.6–11.4ROR 8.1 · χ² 177 / p 1e-40 | 7.3 EB05 5.3 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 9.9 · ♀ 96% (drug 72%) | no trial data cached |
| Eye swelling | 31 | 7.4 5.2–10.5ROR 7.5 · χ² 166 / p 3e-38 | 6.8 EB05 5.0 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.1 | no trial data cached |
| Intraocular pressure increased (raised eye pressure) | 10 | 6.9 3.7–12.8ROR 6.9 · χ² 45 / p 1e-11 | 5.4 EB05 3.1 · IC025 +1.4 3/3 methods agree | Lab value / disease marker | serious PRR 3.2 | no trial data cached |
| Visual acuity reduced | 25 | 6.6 4.5–9.8ROR 6.7 · χ² 114 / p 8e-27 | 6.0 EB05 4.2 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.2 | no trial data cached |
| Pancytopenia (all blood cells low) | 39 | 6.2 4.5–8.5ROR 6.3 · χ² 165 / p 4e-38 | 5.8 EB05 4.4 · IC025 +2.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.8 · ♀ 48% (drug 72%) · 95% clinician | no trial data cached |
| Wrong technique in drug usage process | 25 | 6.0 4.1–8.9ROR 6.1 · χ² 99 / p 1e-23 | 5.4 EB05 3.9 · IC025 +1.8 3/3 methods agree | Reporting / coding artifact | serious PRR 4.9 | no trial data cached |
| Hypophagia | 17 | 5.9 3.7–9.5ROR 6.0 · χ² 65 / p 4e-16 | 5.2 EB05 3.4 · IC025 +1.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.6 | no trial data cached |
| Local swelling | 10 | 5.0 2.7–9.3ROR 5.0 · χ² 28 / p 6e-8 | 4.2 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.2 | no trial data cached |
| Thirst | 10 | 5.0 2.7–9.2ROR 5.0 · χ² 28 / p 7e-8 | 4.1 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.1 | no trial data cached |
| Swelling face | 36 | 4.9 3.5–6.8ROR 5.0 · χ² 108 / p 1e-25 | 4.6 EB05 3.5 · IC025 +1.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.4 | no trial data cached |
| Pain in jaw | 15 | 4.7 2.8–7.8ROR 4.7 · χ² 40 / p 1e-10 | 4.1 EB05 2.7 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.9 | no trial data cached |
| Diplopia (double vision) | 13 | 4.4 2.6–7.6ROR 4.4 · χ² 31 / p 1e-8 | 3.9 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.0 | no trial data cached |
| Lower respiratory tract infection | 22 | 4.3 2.8–6.5ROR 4.3 · χ² 52 / p 2e-13 | 4.0 EB05 2.8 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.5 | no trial data cached |
| Rash pruritic | 25 | 4.1 2.8–6.1ROR 4.1 · χ² 56 / p 4e-14 | 3.8 EB05 2.7 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.3 | no trial data cached |
| Faeces discoloured | 10 | 4.1 2.2–7.6ROR 4.1 · χ² 20 / p 3e-6 | 3.5 EB05 2.1 · IC025 +0.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.8 | no trial data cached |
| Eye disorder | 15 | 4.1 2.4–6.7ROR 4.1 · χ² 32 / p 1e-8 | 3.7 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.8 | no trial data cached |
| Haematemesis (vomiting blood) | 11 | 3.8 2.1–6.9ROR 3.8 · χ² 20 / p 3e-6 | 3.4 EB05 2.0 · IC025 +0.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.0 | no trial data cached |
| Blood creatine phosphokinase increased | 12 | 3.6 2.1–6.4ROR 3.6 · χ² 20 / p 3e-6 | 3.3 EB05 2.0 · IC025 +0.7 3/3 methods agree | Lab value / disease marker | serious PRR 3.1 | no trial data cached |
| Swollen tongue | 12 | 3.4 1.9–6.0ROR 3.4 · χ² 18 / p 1e-5 | 3.1 EB05 1.9 · IC025 +0.7 | No label text to screen label has no adverse-reaction text | serious PRR 3.7 | no trial data cached |
| Sedation | 10 | 3.4 1.8–6.3ROR 3.4 · χ² 15 / p 7e-5 | 3.0 EB05 1.8 · IC025 +0.5 | No label text to screen label has no adverse-reaction text | serious PRR 3.6 | no trial data cached |
| Inappropriate schedule of drug administration | 18 | 2.2 1.4–3.5ROR 2.2 · χ² 11 / p 5e-4 | 2.1 EB05 1.4 · IC025 +0.3 | Reporting / coding artifact | serious PRR 1.0 | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Eye irritation | 162 | 25.8 22.2–29.9ROR 27.6 · χ² 3,833 / p <1e-300 | 25.6 EB05 22.5 · IC025 +4.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 14.7 · 71% consumer | no trial data cached |
| Eye pain | 137 | 22.0 18.7–25.9ROR 23.3 · χ² 2,726 / p <1e-300 | 21.9 EB05 19.0 · IC025 +4.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 11.5 | no trial data cached |
| Vision blurred (blurred vision) | 126 | 8.2 6.9–9.7ROR 8.6 · χ² 790 / p 4e-174 | 8.0 EB05 6.9 · IC025 +2.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.8 | no trial data cached |
| Ocular hyperaemia | 73 | 13.8 11.0–17.4ROR 14.3 · χ² 858 / p 8e-189 | 13.7 EB05 11.2 · IC025 +3.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.5 | no trial data cached |
| Hyponatraemia (low sodium) | 58 | 9.1 7.1–11.8ROR 9.3 · χ² 413 / p 4e-92 | 8.8 EB05 7.0 · IC025 +2.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.3 · ♀ 45% (drug 72%) · 90% clinician | no trial data cached |
| Dry eye | 54 | 9.9 7.6–12.9ROR 10.1 · χ² 422 / p 4e-94 | 9.5 EB05 7.5 · IC025 +2.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 8.9 | no trial data cached |
| Lacrimation increased | 49 | 14.5 11.0–19.2ROR 14.8 · χ² 604 / p 1e-133 | 14.3 EB05 11.2 · IC025 +3.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 9.5 | no trial data cached |
| Eye pruritus | 48 | 12.9 9.7–17.1ROR 13.1 · χ² 515 / p 3e-114 | 12.6 EB05 9.8 · IC025 +3.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 10.8 | no trial data cached |
| Pancytopenia (all blood cells low) | 39 | 6.2 4.5–8.5ROR 6.3 · χ² 165 / p 4e-38 | 5.8 EB05 4.4 · IC025 +2.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.8 · ♀ 48% (drug 72%) · 95% clinician | no trial data cached |
| Swelling face | 36 | 4.9 3.5–6.8ROR 5.0 · χ² 108 / p 1e-25 | 4.6 EB05 3.5 · IC025 +1.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.4 | no trial data cached |
| Photophobia (light sensitivity) | 32 | 15.2 10.8–21.4ROR 15.4 · χ² 410 / p 2e-91 | 14.9 EB05 10.9 · IC025 +3.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.0 | no trial data cached |
| Eye swelling | 31 | 7.4 5.2–10.5ROR 7.5 · χ² 166 / p 3e-38 | 6.8 EB05 5.0 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.1 | no trial data cached |
| Lip swelling | 30 | 8.0 5.6–11.4ROR 8.1 · χ² 177 / p 1e-40 | 7.3 EB05 5.3 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 9.9 · ♀ 96% (drug 72%) | no trial data cached |
| Liver function test abnormal | 30 | 9.1 6.4–13.0ROR 9.2 · χ² 208 / p 2e-47 | 8.4 EB05 6.0 · IC025 +2.4 3/3 methods agree | Reporting / coding artifact | serious PRR 8.8 | no trial data cached |
| Rash pruritic | 25 | 4.1 2.8–6.1ROR 4.1 · χ² 56 / p 4e-14 | 3.8 EB05 2.7 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 6.3 | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Hypromellose?
In FDA FAERS, the most frequently co-reported reaction terms for Hypromellose are eye irritation, eye pain, vision blurred, ocular hyperaemia, hyponatraemia, dry eye. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Hypromellose have an FDA boxed warning?
No. The FDA label retrieved for Hypromellose has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Hypromellose causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 3c1c453e-2644-622a-e063-6394a90a8a94, effective 20250902; matched on
openfda.generic_name.exact:"HYPROMELLOSE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 74 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.